Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):802–806. doi: 10.1038/sj.bjc.6690128

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)

A Kuin 1, M Rutgers 1, M A van der Valk 1, J H Beijnen 1, L A Smets 1
PMCID: PMC2362668  PMID: 10070872

Abstract

meta-iodobenzylguanidine (MIBG) radiolabelled with iodine-131 is used for diagnosis and treatment of neuroadrenergic neoplasms such as phaeochromocytoma and neuroblastoma. In addition, non-radiolabelled MIBG, administered i.v., is used in several clinical studies. These include palliation of the carcinoid syndrome, in which MIBG proved to be effective in 60% of the patients. Oral MIBG administration might be convenient to maintain palliation and possibly improve the percentage of responders. We have, therefore, investigated the feasibility of oral administration of MIBG in an animal model. Orally administered MIBG demonstrated a bioavailability of 59%, with a maximal tolerated dose of 60 mg kg−1. The first and only toxicity encountered was a decrease in renal function, measured by a reduced clearance of [51Cr]EDTA and accompanied by histological tubular damage. Repeated MIBG administration of 40 mg kg−1for 5 sequential days or of 20 mg kg−1for two courses of 5 sequential days with a 2-day interval did not affect renal clearance and was not accompanied by histological abnormalities in kidney, stomach, intestines, liver, heart, lungs, thymus, salivary glands and testes. Because of a sufficient bioavailability in absence of gastrointestinal toxicity, MIBG is considered suitable for further clinical investigation of repeated oral administration in patients. 1999 Cancer Research Campaign

Keywords: MIBG, oral administration, bioavailability, toxicity, carcinoid syndrome

Full Text

The Full Text of this article is available as a PDF (87.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Hoefnagel C. A., Voûte P. A., de Kraker J., Marcuse H. R. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med. 1987 Mar;28(3):308–314. [PubMed] [Google Scholar]
  2. Hoefnagel C. A., den Hartog Jager F. C., Taal B. G., Abeling N. G., Engelsman E. E. The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med. 1987;13(4):187–191. doi: 10.1007/BF00256489. [DOI] [PubMed] [Google Scholar]
  3. Jaques S., Jr, Tobes M. C., Sisson J. C. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res. 1987 Aug 1;47(15):3920–3928. [PubMed] [Google Scholar]
  4. Kuin A., Aalders M., van der Valk M. A., Frey A., Schmidt H. H., Smets L. A. Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine. Cancer Chemother Pharmacol. 1998;42(1):37–45. doi: 10.1007/s002800050782. [DOI] [PubMed] [Google Scholar]
  5. Kuin A., Smets L., Volk T., Paans A., Adams G., Atema A., Jähde E., Maas A., Rajewsky M. F., Visser G. Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia. Cancer Res. 1994 Jul 15;54(14):3785–3792. [PubMed] [Google Scholar]
  6. Loesberg C., Van Rooij H., Nooijen W. J., Meijer A. J., Smets L. A. Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG). Int J Cancer. 1990 Aug 15;46(2):276–281. doi: 10.1002/ijc.2910460223. [DOI] [PubMed] [Google Scholar]
  7. Loesberg C., van Rooij H., Smets L. A. Meta-iodobenzylguanidine (MIBG), a novel high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation). Biochim Biophys Acta. 1990 Jan 19;1037(1):92–99. doi: 10.1016/0167-4838(90)90106-p. [DOI] [PubMed] [Google Scholar]
  8. Rutgers M., Tytgat G. A., Verwijs-Janssen M., Buitenhuis C., Voûte P. A., Smets L. A. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells. Int J Cancer. 1993 May 8;54(2):290–295. doi: 10.1002/ijc.2910540221. [DOI] [PubMed] [Google Scholar]
  9. Sisson J. C., Wieland D. M. Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical studies. Am J Physiol Imaging. 1986;1(2):96–103. [PubMed] [Google Scholar]
  10. Smets L. A., Bout B., Wisse J. Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG). Cancer Chemother Pharmacol. 1988;21(1):9–13. doi: 10.1007/BF00262730. [DOI] [PubMed] [Google Scholar]
  11. Smets L. A., Janssen M., Rutgers M., Ritzen K., Buttenhuis C. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells. Int J Cancer. 1991 Jun 19;48(4):609–615. doi: 10.1002/ijc.2910480421. [DOI] [PubMed] [Google Scholar]
  12. Sparreboom A., van Asperen J., Mayer U., Schinkel A. H., Smit J. W., Meijer D. K., Borst P., Nooijen W. J., Beijnen J. H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031–2035. doi: 10.1073/pnas.94.5.2031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Taal B. G., Hoefnagel C. A., Valdes Olmos R. A., Boot H., Beijnen J. H. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996 Jun;14(6):1829–1838. doi: 10.1200/JCO.1996.14.6.1829. [DOI] [PubMed] [Google Scholar]
  14. Wafelman A. R., Hoefnagel C. A., Maes R. A., Beijnen J. H. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994 Jun;21(6):545–559. doi: 10.1007/BF00173043. [DOI] [PubMed] [Google Scholar]
  15. Wieland D. M., Wu J., Brown L. E., Mangner T. J., Swanson D. P., Beierwaltes W. H. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980 Apr;21(4):349–353. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES